Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

  • Hani Babiker
  • , Erkut Borazenci
  • , Vivek Subbiah
  • , Sanjiv Agarwala
  • , Alain Algazi
  • , Jacob Schachter
  • , Michael Lotem
  • , Corinne Maurice-Dror
  • , Daniel Hendler
  • , Shah Rahimian
  • , Hans Minderman
  • , Cara Haymaker
  • , Daruka Mahadevan
  • , Chantale Bernatchez
  • , Ravi Murthy
  • , Rolf Hultsch
  • , Nadia Kaplan
  • , Gregory Woodhead
  • , Charles Hennemeyer
  • , Srinivas Chunduru
    • Peter M. Anderson, Adi Diab, Igor Puzanov

Producción científica: Article › revisión exhaustiva

10   !!Link opens in a new tab Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)'. En conjunto forman una huella única.
Clasificar por

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology